DelveInsight’s, “Influenza Pipeline Insight, 2023,” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Influenza pipeline landscape. It covers the Influenza pipeline drug profiles, including Influenza clinical trials and nonclinical stage products. It also covers the Influenza pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Influenza Pipeline Insight Report, a detailed description of the drug is given which includes mechanism of action of the drug, Influenza clinical trial studies, Influenza NDA approvals (if any), and product development activities comprising the technology, Influenza collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Influenza Pipeline Insight Report
To explore more information on the latest breakthroughs in the Influenza Pipeline treatment landscape of the report, click here @ Influenza Pipeline Outlook
Recent Developmental Activities in the Influenza Treatment Landscape
Influenza Overview
Influenza, one of the most common infectious diseases, is a highly contagious airborne disease that occurs in seasonal epidemics and manifests as an acute febrile illness with variable degrees of systemic symptoms, ranging from mild fatigue to respiratory failure and death. Influenza causes significant loss of workdays, human suffering, and mortality. The CDC documented that seasonal influenza was responsible for 24,000 to 62,000 deaths during the 2019-2020 season. Information used to generate influenza in-season burden estimates were too low during the 2020-2021 season to provide an estimate. Mortality was highest in infants and elderly persons. Influenza traditionally has been diagnosed on the basis of clinical criteria, but rapid diagnostic tests, which have a high degree of specificity but only moderate sensitivity, are becoming more widely used.
Request a sample and discover the recent advances in Influenza Ongoing Clinical Trial Analysis and Medications, click here @ Influenza Treatment Landscape
Influenza Emerging Drugs Profile
mRNA-1010: Moderna
mRNA-1010 is a vaccine candidate that encodes for hemagglutinin (HA) glycoproteins of the four influenza strains recommended by the World Health Organization (WHO) for the prevention of influenza, including influenza A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages. HA is a major influenza surface glycoprotein that is considered an important target to generate broad protection against influenza and is the primary target of currently available influenza vaccines. Currently, it is in Phase III stage of clinical trial evaluation to treat patients suffering from Seasonal Influenza.
SAB-176: SAB Biotherapeutics
SAB-176 is a quadrivalent broadly neutralizing fully-human polyclonal antibody therapeutic candidate that leverages the human biological immune response in development for the treatment of hospitalized patients with severe seasonal influenza. The novel specifically targeted therapeutic generated from the company’s proprietary technology, the DiversitAb™ platform, is designed to specifically bind to Type A and Type B influenza viruses. Pre-clinical data suggests that SAB-176 offers potentially broad protection against diverse influenza strains. A highly-potent, polyclonal antibody therapy for severe seasonal influenza, could potentially treat severely ill patients and provide protective antibodies for high-risk populations, such as the elderly and immune compromised.
INNA-051: ENA Respiratory Pty Ltd
INNA-051 is a broad-spectrum antiviral immunomodulatory nasal spray under clinical development for pre- and post-exposure prophylaxis of respiratory viral infections in populations at risk of severe complications. Based on its mechanism of action and intended route of administration, INNA-051 has the potential to address several viral respiratory pathogens across multiple patient populations with a variety of co-morbid conditions. INNA-051 antiviral efficacy is currently evaluated in a Phase 2a influenza-challenge conducted in healthy volunteers.
CODA-VAX H1N1: Codagenix
Codagenix has utilized a design platform to construct a live-attenuated, universal flu vaccine, CodaVax™-H1N1. The vaccine enables presentation of conserved antigens of the wild-type virus, demonstrating universal potential in primate models and thus the potential to provide multi-season protection when developed into its final quadrivalent formulation. Currently, it is being evaluated in Phase I stage of clinical trial evaluation to treat Influenza virus infections.
ALVR106: AlloVir
ALVR106 is an allogeneic, off-the-shelf, multi-virus specific VST therapy candidate designed to target diseases caused by the respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). In vitro data demonstrates that ALVR106 reactive cells have antiviral activity against each of the targeted viruses with minimal or no activity against non-virus-infected cells. This preclinical data supports the potential for antiviral benefit and safety of ALVR106 when administered to patients.
Influenza Pipeline Therapeutic Assessment
There are approx. 120+ key companies which are developing the therapies for Influenza. The companies which have their Influenza drug candidates in the most advanced stage, i.e. phase III include, Moderna.
For further information, refer to the detailed Influenza Unmet Needs, Influenza Market Drivers, and Market Barriers, click here for Influenza Ongoing Clinical Trial Analysis
Scope of the Influenza Pipeline Report
Dive deep into rich insights for drugs for Influenza Market Drivers and Influenza Market Barriers, click here @ Influenza Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Influenza Mergers and acquisitions, Influenza licensing activities @ Influenza Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services